Resvita Bio Inc.
Emeryville, CA
- UEI
- LE1LFZE6EMK5
- CAGE
- 20SB5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1261 64th St Apt B, Emeryville, CA 94608, USA
- Website
- resvitabio.com
- Founded
- 2021
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Consumer Discretionary
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Unlocked Labs Inc. | Laramie, WY | — |
| Fzata Inc. | Halethorpe, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Topaz Biosciences, Inc. | Emeryville, CA | — |
| Fibrobiologics LLC | Charleston, SC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Akanocure Pharmaceuticals Inc. | West Lafayette, IN | — |
About the company
Resvita Bio Inc. is a for-profit corporate entity registered in the System for Award Management (SAM.gov) since March 2022, with registration valid through March 2025. The company appears to be a biotechnology research organization focused on developing innovative therapeutic solutions using genetically engineered bacteria for treating complex skin conditions. While specific details about the company's full organizational structure are not provided, the federal grant awards suggest a strong emphasis on synthetic biology and microbiome-based medical interventions.
Resvita Bio Inc. has received multiple federal grant awards from civilian health agencies, specifically the National Institute of Allergy and Infectious Diseases and the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The company's primary research focus involves developing skin probiotic technologies to treat genetic and inflammatory skin disorders such as Netherton Syndrome and Atopic Dermatitis. Their approach centers on genetically engineering harmless bacteria to temporarily populate the skin microbiome and deliver targeted enzyme inhibitors, specifically focusing on modulating serine protease activity. The grants, structured as Small Business Innovation Research (SBIR) Phase I and Phase II awards, demonstrate a progressive research strategy aimed at developing novel topical treatments. The most recent grant, awarded on July 1, 2023, for the Atopic Dermatitis project (R43AI179327), has an ultimate completion date of June 30, 2024, while an earlier Netherton Syndrome project (R44AR082240) is scheduled to complete by August 30, 2026. These grants, totaling approximately $2-3 million, support the company's innovative approach to developing continuous, localized peptide drug production mechanisms for challenging skin conditions.
Quick answers
Is Resvita Bio Inc. registered in SAM.gov?
Yes. Resvita Bio Inc.'s SAM.gov registration is active through May 19, 2027.
What is Resvita Bio Inc.'s most recent federal award?
Resvita Bio Inc.'s most recent federal grant award is Skin probiotics to treat atopic dermatitis (R44AI179327), from National Institute of Allergy and Infectious Diseases (NIH), on July 1, 2023.
On GovTribe
See Resvita Bio Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors